News
Displaying 141–150 of 536
-
Opus Genetics to Launch Gene Therapy Clinical Trial for LCA5 Patients
Research NewsThe LCA5 gene therapy will be the first emerging Opus treatment to move into a human study
-
Your Dollar Makes a Difference
Foundation NewsAt the Foundation Fighting Blindness, a dollar is more than just a dollar – it’s a path to transforming lives. But just where does your donation go?
-
Editas Reports Results for 14 Participants in its Phase 1/2 CRISPR/Cas9 Clinical Trial for LCA10
Research NewsThe company is seeking a partner to move the LCA10 program forward
-
Foundation News
Uni-Rare Study will improve clinical understanding of more IRDs and boost development of potential therapies.
-
In the Press
On World Sight Day 2022, Retina International is presenting data from a report on its study into the Socio-economic Impact of late-stage age-related macular degeneration (AMD) in Bulgaria, Germany, and USA.
-
Recap of Retinal Disease News from the 2022 Meeting of the American Academy of Ophthalmology
Research NewsReports on emerging therapies for dry age-related macular degeneration (geographic atrophy), Stargardt disease, and X-linked retinitis pigmentosa are included
-
Atsena’s LCA-GUCY2D Gene Therapy Improves Vision in Phase 1/2 Clinical Trial
Research NewsThe company is planning to move the emerging treatment into a pivotal trial
-
Research News
Small data sets present challenges for developing rare disease AI tools
-
Foundation News
Initiatives to increase engagement and awareness around blinding retinal diseases.
-
RD Fund Participates in a €75 Million Series B for SparingVision
In the PressProceeds to fund first, in-human trials of breakthrough gene-agnostic therapy products and advance CRISPR-based genome editing portfolio.
.png)
